Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Forte Biosciences, Inc.FBRX · Entity 9529 | Director | August 20, 2024 | August 22, 2024 |
| Verrica Pharmaceuticals Inc.VRCA · Entity 6823 | Director | June 05, 2026 | June 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Forte Biosciences, Inc.
Report date August 20, 2024 · Filed August 22, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.34 · Expires 2034-08-20 | Direct | 50,000 |
Reported balance
After 2024-08-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-08-20 · Grant · Acquired 50,000 · Balance 50,000 F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean August 20, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean August 20, 2024.
Verrica Pharmaceuticals Inc.
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.04 · Expires 2036-06-04 | Direct | 16,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 16,000 · Balance 16,000 F1: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 5, 2026 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 5, 2026 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 9, 2026 20:15 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $6.04 | $0.00 |
DisclosureSEC source: 0001814892-26-000002 · form4-06092026_040606.xml · derivative · entry 1 Eichenfield Lawrence · CIK 0001814892 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2036-06-04 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 5, 2026 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:45 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001415889-25-016287 · form4-06092025_040601.xml · derivative · entry 1 Eichenfield Lawrence · CIK 0001814892 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 5, 2025 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:12 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.34 | $0.00 |
DisclosureSEC source: 0001415889-24-022010 · form4-08222024_080856.xml · derivative · entry 1 Eichenfield Lawrence · CIK 0001814892 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-08-20 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean August 20, 2024. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:15 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $8.78 | $0.00 |
DisclosureSEC source: 0001415889-24-015959 · form4-06072024_040609.xml · derivative · entry 1 Eichenfield Lawrence · CIK 0001814892 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-06-05 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 6, 2024 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 21:49 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001209191-23-050191 · doc4.xml · derivative · entry 1 Eichenfield Lawrence · CIK 0001814892 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-09-19 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean September 19, 2023. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 13:03 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (right to buy) · Derivative | 10,384 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0001209191-23-036149 · doc4.xml · derivative · entry 1 Eichenfield Lawrence · CIK 0001814892 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,384 Underlying: Common Stock · 10,384 shares Expires 2033-06-07 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 8, 2023 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:17 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (right to buy) · Derivative | 10,384 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001209191-22-036297 · doc4.xml · derivative · entry 1 Eichenfield Lawrence · CIK 0001814892 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,384 Underlying: Common Stock · 10,384 shares Expires 2032-06-08 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 9, 2022 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 21:09 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001209191-22-033616 · doc4.xml · derivative · entry 1 Eichenfield Lawrence · CIK 0001814892 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-01 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean June 1, 2022. Read SEC document |
| February 23, 2022 Filed Feb 24, 2022 22:02 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001209191-22-012742 · doc4.xml · derivative · entry 1 Eichenfield Lawrence · CIK 0001814892 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-02-23 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the one (1) year anniversary of the Date of Grant. "Date of Grant" shall mean February 23, 2022. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:56 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (right to buy) · Derivative | 5,834 | $0.00 Strike: $10.56 | $0.00 |
DisclosureSEC source: 0001209191-21-040265 · doc4.xml · derivative · entry 1 Eichenfield Lawrence · CIK 0001814892 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,834 Underlying: Common Stock · 5,834 shares Expires 2031-06-09 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 10, 2021 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date. Read SEC document |
| June 10, 2021 Filed Jun 17, 2021 20:31 UTC Amendment | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (right to buy) · Derivative | 8,109 | $0.00 Strike: $10.56 | $0.00 |
DisclosureSEC source: 0001209191-21-041443 · doc4a.xml · derivative · entry 1 Eichenfield Lawrence · CIK 0001814892 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,109 Underlying: Common Stock · 8,109 shares Expires 2031-06-09 F1 · shares: The original Form 4 filed on June 14, 2021 inadvertently listed the incorrect number of options granted to the Reporting Person. This amendment is being file to accurately reflect the true number of options granted. F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 10, 2021 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date. F1 · derivative.underlying_shares: The original Form 4 filed on June 14, 2021 inadvertently listed the incorrect number of options granted to the Reporting Person. This amendment is being file to accurately reflect the true number of options granted. F1 · balance_after: The original Form 4 filed on June 14, 2021 inadvertently listed the incorrect number of options granted to the Reporting Person. This amendment is being file to accurately reflect the true number of options granted. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 23:33 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $35.54 | $0.00 |
DisclosureSEC source: 0000899243-21-021419 · doc4.xml · derivative · entry 1 Eichenfield Lawrence · CIK 0001814892 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-05-28 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean May 28, 2021. Read SEC document |
| August 01, 2020 Filed Aug 3, 2020 22:34 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (right to buy) · Derivative | 17,502 | $0.00 Strike: $6.56 | $0.00 |
DisclosureSEC source: 0001209191-20-044548 · doc4.xml · derivative · entry 1 Eichenfield Lawrence · CIK 0001814892 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,502 Underlying: Common Stock · 17,502 shares Expires 2030-07-31 F1 · derivative.exercise_date: 1/3rd of the total shares subject to the option shall vest on August 1, 2021 and 1/36th of the total shares subject to the option shall vest monthly thereafter over the remaining two years of the vesting period, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 15, 2020 Filed Jun 18, 2020 00:54 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0000899243-20-016935 · doc4.xml · derivative · entry 1 Eichenfield Lawrence · CIK 0001814892 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-06-15 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2017 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the Date of Grant. "Date of Grant" shall mean June 15, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.